BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20049837)

  • 1. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.
    Perkins G; Lièvre A; Ramacci C; Méatchi T; de Reynies A; Emile JF; Boige V; Tomasic G; Bachet JB; Bibeau F; Bouché O; Penault-Llorca F; Merlin JL; Laurent-Puig P
    Int J Cancer; 2010 Sep; 127(6):1321-31. PubMed ID: 20049837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
    Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers.
    Harlé A; Salleron J; Perkins G; Pilati C; Blons H; Laurent-Puig P; Merlin JL
    Br J Cancer; 2015 Aug; 113(4):680-5. PubMed ID: 26171935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
    Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
    Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
    Berg M; Soreide K
    Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.
    Modest DP; Jung A; Moosmann N; Laubender RP; Giessen C; Schulz C; Haas M; Neumann J; Boeck S; Kirchner T; Heinemann V; Stintzing S
    Int J Cancer; 2012 Aug; 131(4):980-6. PubMed ID: 21960311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
    Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
    Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
    Tímár J; Láng I
    Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.
    Adelstein BA; Dobbins TA; Harris CA; Marschner IC; Ward RL
    Eur J Cancer; 2011 Jun; 47(9):1343-54. PubMed ID: 21550229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
    Peeters M; Siena S; Van Cutsem E; Sobrero A; Hendlisz A; Cascinu S; Kalofonos H; Devercelli G; Wolf M; Amado RG
    Cancer; 2009 Apr; 115(7):1544-54. PubMed ID: 19189371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
    Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S
    Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.
    Cejas P; López-Gómez M; Aguayo C; Madero R; Moreno-Rubio J; de Castro Carpeño J; Belda-Iniesta C; Barriuso J; Moreno García V; Díaz E; Burgos E; Gonzalez-Barón M; Feliu J
    Curr Cancer Drug Targets; 2012 Feb; 12(2):124-31. PubMed ID: 22229245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association of epithermal growth factor receptor expression and its downstream gene mutation status with radiosensitivity of colorectal carcinoma cell lines in vitro].
    Zuo ZG; Yu ZQ; Gao XH; Wang H; Zhang C; Liu QZ; Han YF; Chen LP; Zhang XQ; Fu CG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Aug; 16(8):753-8. PubMed ID: 23980047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
    Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
    Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy.
    Kim ST; Park KH; Kim JS; Shin SW; Kim YH
    Cancer Res Treat; 2013 Mar; 45(1):55-62. PubMed ID: 23613671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment].
    Shimodaira H; Soeda H; Komine K; Ishioka C
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1063-6. PubMed ID: 19620792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized cancer treatment and the myth of KRAS wild-type colon tumors.
    Parsons BL; Myers MB
    Discov Med; 2013 Apr; 15(83):259-67. PubMed ID: 23636143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.
    Roda D; Castillo J; Telechea-Fernández M; Gil A; López-Rodas G; Franco L; González-Rodríguez P; Roselló S; Pérez-Fidalgo JA; García-Trevijano ER; Cervantes A; Zaragozá R
    PLoS One; 2015; 10(6):e0130543. PubMed ID: 26110767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells.
    Unson S; Chang TC; Yang YN; Wang SH; Huang CH; Crawford DR; Huang HM; Li ZL; Lin HY; Whang-Peng J; Wang K; Davis PJ; Li WS
    Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.